Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

BACKGROUND: Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are lacking. METHODS: Previously untreated patients with non-resectable mCRC were t...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Alexander, Kretzschmar, Albrecht, Behringer, Dirk, Wolff, Thomas, Zimber, Joachim, Hegewisch-Becker, Susanna, Kettner, Erika, Pflüger, Karl-Heinz, Kirsch, Andreas, Arnold, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850951/
https://www.ncbi.nlm.nih.gov/pubmed/24090011
http://dx.doi.org/10.1186/1471-2407-13-454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850951/
https://www.ncbi.nlm.nih.gov/pubmed/24090011
http://dx.doi.org/10.1186/1471-2407-13-454

Ejemplares similares